Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib + Irinotecan +/- Temozolomide in Pediatric Solid Tumors
NCT02392793Phase 1Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Mar 2015
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of talazoparib in solid tumor (2 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoints: Maximum Tolerated Dose at 21 days and Dose-Limiting Toxicities at 21 days. Started Mar 2015; status: completed.
02
Drugs
talazoparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02392793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02392793.